Surgical technology company Proprio earned its second major FDA 510(k) clearance to include intraoperative measurements for its Paradigm platform.
Paradigm is an AI-guided surgical platform that enables 3D, dynamic and segmental viewing of anatomy, according to an April 8 news release from Proprio.
With the clearance, Paradigm displays real-time progress compared to pre-operative plans and lets surgeons know when they have reached their goals, leading to improved patient outcomes.
The platform received its first FDA clearance in 2023 and has been used in more than 50 spine cases.
